Buying The Coronavirus Vaccine: What Would A ‘Fair And Reasonable’ Price Be?
Executive Summary
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.
You may also be interested in...
Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry
Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.
Federal Official Would Monitor 'Price Gouging’ Under Latest US House Pandemic Relief Bill
Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.
'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill
Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.